Transition Therapeutics (Transition) has dosed the first patient in a Phase ll trial of its selective androgen receptor modulator (SARM) drug candidate TT701.

The study will assess the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue / low vitality, and physical dysfunction in men with prostate cancer who have undergone radical prostatectomy for organ-localised prostate cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Phase ll clinical trial is being conducted at Brigham and Women’s Hospital (BWH), US, led by principal investigator Dr Shalender Bhasin from BWH and will enrol up to 125 subjects at selected specialised clinical sites including BWH.

BWH research programme in men’s health: aging and metabolism director Shalender Bhasin said: "Sexual dysfunction, fatigue and other distressing symptoms of testosterone deficiency can greatly reduce the quality of life for men who have undergone radical prostatectomy for organ localised disease.

"The dosing of the first patient in this study is expected to generate a payment of $500,000 to Lilly."

"Therefore, the ability to treat these symptoms safely is an important unmet need."

The company stated that its wholly-owned subsidiary, Transition Therapeutics Ireland has exclusively licensed worldwide rights to the TT701 drug candidate from Eli Lilly and Company (Lilly).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The dosing of the first patient in this study is expected to generate a payment of $500,000 to Lilly.

Transition further noted that prostate cancer is the most common malignancy in American men, accounting for 29% of all diagnosed cancers and around 13% of all cancer deaths.

Its incidence is on the rise, partly due to increased screening with Prostate-specific antigen (PSA).

The majority of these men have low-grade, organ-confined prostate cancer and good prospects of long-term survival.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now